Working Together to Understand, Protect and Restore Vision
Using a stem cell-derived therapeutic developed over more than a decade in Dr. David Gamm’s lab at UW–Madison, BlueRock Therapeutics has treated the first patient in a new Phase 1/2a clinical trial aimed at a group of inherited retinal disorders (including RP and cone-rod dystrophy). The initiative is the result of a strategic research alliance formed in …
MERI member Karen Schloss (UW Department of Psychology and Wisconsin Institute for Discovery), recently sat down with WPR’s The Larry Meiller Show to discuss her research on how colors influence meaning, behavior, and emotion. Listen to the whole interview here.
A recent study by the Hoon lab published in Current Biology has uncovered new modes of retinal circuit compensation and adaptation in response to impairments seen in congenital stationary night blindness (CSNB). CSNB is a retinal disease where input to a primary retinal pathway is suppressed. Using mouse models that mimic different stages of disease severity, partial …